A randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome.
Journal of neurodevelopmental disorders January 24, 2025 Kathleen Campbell, Jeffrey L Neul, David N Lieberman et al. 5 citations
Preclinical studies and anecdotal case reports support the potential therapeutic benefit of low-dose oral ketamine as a treatment of clinical symptoms in Rett syndrome (RTT); however, no controlled studies have been conducted in RTT to evaluate safety, tolerability and efficacy. This was a sequentially initiated, dose-escalating cohort, placebo-controlled, double blind, randomized sequence,...